Showing results (41-50 of 58) with videos related to
Sort By:
Pageof 6
AIDS (London, England)|September 14, 2000
Rapid activation of lymph nodes and mononuclear cell HIV expression upon interrupting highly active antiretroviral therapy in patients after prolonged viral suppressionJ M Orenstein, N Bhat, C Yoder, et al.Pharmacotherapy|December 28, 1999
Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction studyJ Falloon, S Sargent, S C Piscitelli, et al.The New England Journal of Medicine|October 31, 1996
Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virusJ A Kovacs, S Vogel, J M Albert, et al.The Journal of Infectious Diseases|April 1, 1997
Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected personsR T Davey, D G Chaitt, S C Piscitelli, et al.Clinical Immunology (Orlando, Fla.)|April 5, 2001
Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansionK D Miller, K Spooner, B R Herpin, et al.Nature Medicine|May 1, 1997
HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapiesM Connors, J A Kovacs, S Krevat, et al.The Journal of Infectious Diseases|July 1, 1996
Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1R E Walker, K M Spooner, G Kelly, et al.The Journal of Infectious Diseases|April 1, 1996
Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: results of a phase I/II trialJ A Kovacs, C Bechtel, R T Davey, et al.The Journal of Infectious Diseases|September 9, 2000
Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expressionJ A Kovacs, H Imamichi, S Vogel, et al.Antimicrobial Agents and Chemotherapy|August 1, 1997
Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infectionM A Polis, S C Piscitelli, S Vogel, et al.Pageof 6